Anti-infection Therapy Based on mNGS Etiological Diagnosis and Infection After Liver Transplantation - Trial NCT06212115
Access comprehensive clinical trial information for NCT06212115 through Pure Global AI's free database. This phase not specified trial is sponsored by Shenzhen Third People's Hospital and is currently Not yet recruiting. The study focuses on Infection. Target enrollment is 300 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shenzhen Third People's Hospital
Timeline & Enrollment
N/A
Feb 01, 2024
Dec 30, 2027
Primary Outcome
Infection
Summary
Liver transplantation is the most efficacious treatment for end-stage liver disease; however,
 postoperative infection remains a major complication and leading cause of recipient
 mortality. Specifically, infections originating from donors, particularly those caused by
 multidrug-resistant bacteria, can significantly impact the prognosis of liver transplant
 recipients. Theoretically, implementing targeted antimicrobial therapy for donors prior to
 organ donation could reduce the likelihood of pathogen transmission with the transplanted
 organ, thereby potentially decreasing the incidence of post-transplant infections from donor
 sources and improving recipient outcomes. Nevertheless, there is currently a dearth of
 high-quality prospective studies in this domain. Our previous investigation (Front Microbiol.
 2022 Jul 1;13:919363) demonstrated that second-generation metagenomic sequencing (mNGS)
 technology holds substantial value in expeditious pathogen screening following liver
 transplantation. Prompt implementation of targeted treatment based on microbiological
 findings has shown potential to enhance outcomes for select recipients. Therefore, this study
 aims to provide tailored treatment for donors based on microbiological examination results
 (including mNGS detection and culture results), analyze corresponding data regarding
 recipient infection occurrence and prognosis, and explore the impact of mNGS-guided donor
 antimicrobial therapy on perioperative infection rates among liver transplant recipients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06212115
Non-Device Trial